SPARK: A Health Data Integration Platform for Pancreatic Cancer Research

By Kawther Abdilleh, PhD - Last Updated: March 19, 2025

Kawther Abdilleh, PhD, Director, Data Science and Informatics, Pancreatic Cancer Action Network (PanCAN), discusses the Pancreatic Cancer Action Network’s new cloud-based data and analytics program for pancreatic cancer research. Dr. Abdilleh highlights the platform’s comparison features and discusses how the program will move forward following the pilot phase.

Neoadjuvant Chemotherapy Shows Promise for Treatment of Patients With Resectable Pancreatic Adenocarcinoma

Jessica GangaPancreatic Cancer | May 16, 2025

Researchers evaluated the use of mFOLFIRINOX for the treatment of patients with resectable pancreatic adenocarcinoma.

Breaking Silos, Building Impact: Dr. Bassel El-Rayes on Advancing Pancreatic and Neuroendocrine Cancer Research

Bassel El-Rayes, MDPancreatic Cancer | April 29, 2025

Dr. El-Rayes reflects on his career in translational research, emphasizing his efforts to expand trial infrastructure.

The Efficacy of PARP Inhibitors for DDR Deficiencies in Metastatic Pancreatic Cancer

James Cleary, MD, PhDPancreatic Cancer | April 17, 2025

Dr. Cleary discusses DDR deficiencies in metastatic pancreatic cancer and reviews the use of PARP inhibitors.

Zenocutuzumab Safety, Efficacy for NRG1 Fusion-Positive Pancreatic Cancer: Low-Grade AEs

Emily MenendezPancreatic Cancer | April 15, 2025

Zenocutuzumab may serve as an effective treatment for NRG1 fusion-positive pancreatic cancer, with low-grade AEs.

Zenocutuzumab for Pancreatic Cancer: Toxicity Concerns and Ongoing Research

Stephen Liu, MDPancreatic Cancer | April 15, 2025

Drs. Stephen Liu and Benjamin Weinberg continue their discussion on the safety of zenocutuzumab in NRG1 fusion+ PDAC.

SPARK: A Health Data Integration Platform for Pancreatic Cancer Research

Related Posts